SRC and ovarian cancer: To dissect the signaling pathway that mediates HER2-induced cancer stem cells in ovarian cancer, SKOV3 cells were treated with inhibitors for classic downstream pathways of HER2, including LY294002 (PI3K/AKT inhibitor,10 μM), PD0325901 (MAPK inhibitor, 100 nM), JSH23 (NFκB inhibitor, 20 μM), and PP2 (SRC inhibitor, 10 μM).